Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. (HALO) Shares Outstanding — Overview
Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.
HALO · shares outstanding · updated Jun 8, 2026
Key metrics
as of Dec 31, 2025Shares Outstanding Growth Rate
CAGR · weighted avg basic sharesNegative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials
Shares outstanding history
Annual shares outstanding by year
Healthcare sector shares outstanding comparison
Shares Outstanding for similar companies or competitors in the Healthcare sector.
MRK
JNJ
ABBV
AZN
UNH
LLYHALO/company-screener · per-peer /income-statement · cache 86400s
Understanding Shares Outstanding
Basic · Diluted · FloatWhat Are Shares Outstanding? (Basic)
Halozyme Therapeutics, Inc. (HALO) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2025, Halozyme Therapeutics, Inc. reports 119.8M basic shares outstanding (weighted average).
Basic vs. Diluted Shares Outstanding
Halozyme Therapeutics, Inc.'s basic shares outstanding (119.8M) represents currently issued shares. Diluted shares outstanding (123.9M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +3.39%.
Shares Outstanding vs. Float (Free Float)
Halozyme Therapeutics, Inc.'s float is 117.3M (98.8% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.
ⓘ Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.
FMP /income-statement · /shares-float · SEC EDGAR · USD
About shares outstanding & methodology
Halozyme Therapeutics, Inc. (HALO) shares outstanding history from 2006 to 2025. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.
Halozyme Therapeutics, Inc. shares outstanding for the fiscal year ending December 31, 2025 were 119.8M, a 5.51% decline year-over-year. Halozyme Therapeutics, Inc. FY 2025 shares outstanding were 119.8M, a -5.51% decline from FY 2024.
Halozyme Therapeutics, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of -0.6% — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.
Frequently asked questions
HALO shares outstanding · 4 questionsAs of December 31, 2025, Halozyme Therapeutics, Inc. (HALO) has approximately 119.8M basic shares outstanding and 123.9M diluted shares outstanding. This represents a -5.51% year-over-year change from FY 2024 (126.8M). Halozyme Therapeutics, Inc.'s declining share count is primarily driven by its share buyback program. For the complete historical data table, see the history table above.
▸ Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Halozyme Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-08